Abstract
Purpose
Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. Rats subjected to permanent lymph duct cannulation were used to investigate the effects of ezetimibe on lipid transport.
Methods
Rats were fed diets with and without ezetimibe (5.0 mg/kg), and their lymph was collected after feeding to quantify lymphatic lipid levels. Total cholesterol content in the intestinal mucosa was also measured.
Results
Rats that consumed ezetimibe had significantly lower lymphatic total cholesterol transport with the reduction of esterified cholesterol transport. According to the calculation based on cholesterol consumption, ezetimibe reduced the total cholesterol lymphatic recovery rate by 54 %. We also determined that ezetimibe significantly reduced the total cholesterol content in the intestinal mucosa.
Conclusion
This is the first direct evidence that ezetimibe inhibits esterified but not free cholesterol lymphatic transport in thoracic duct-cannulated rats. The results also indicate that ezetimibe is not involved in the lymphatic transport of triacylglycerols, phospholipids, or α-tocopherol.
This is a preview of subscription content, log in via an institution to check access.
References
Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem. 2004;47:1–9.
Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102:8132–7.
Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008;7:508–19.
van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001;134:409–17.
Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943–8.
Imaizumi K, Havel RJ, Fainaru M, Vigne JL. Origin and transport of the A-I and arginine-rich apolipoproteins in mesenteric lymph of rats. J Lipid Res. 1978;19:1038–46.
Tso P. Gastrointestinal digestion and absorption of lipid. Adv Lipid Res. 1985;21:143–86.
Carey MC, Hernell O. Digestion and absorption of fat. Semin Gastrointest Dis. 1992;3:189–208.
Shirouchi B, Kawamura S, Matsuoka R, et al. Dietary guar gum reduces lymph flow and diminishes lipid transport in thoracic duct-cannulated rats. Lipids. 2011;46:789–93.
Sato M, Ueda T, Nagata K, et al. Dietary kakrol (Momordica dioica Roxb.) flesh inhibits triacylglycerol absorption and lowers the risk for development of fatty liver in rats. Exp Biol Med (Maywood). 2011;236:1139–46.
American Institute of Nutrition. Report of the American Institute of Nurtition ad hoc Committee on Standards for Nutritional Studies. J Nutr. 1977;107:1340–8.
van Heek M, Farley C, Compton DS, Hoos LM, Smith-Torhan A, Davis HR. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol. 2003;138:1459–64.
Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497–509.
Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem. 1993;26:39–42.
Burrier RE, Smith AA, McGregor DG, Hoos LM, Zilli DL, Davis Jr HR. The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine. J Pharmacol Exp Ther. 1995;272:156–63.
Martins IJ, Mortimer BC, Redgrave TG. Effect of the ACAT inhibitor CL 277,082 on apolipoprotein B48 transport in mesenteric lymph and on plasma clearance of chylomicrons and remnants. Arterioscler Thromb Vasc Biol. 1997;17:211–6.
Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 1998;97:2519–26.
Satoh A, Adachi H, Tsuruta M, Hirai Y, Hiratsuka A, Enomoto M, Furuki K, Hino A, Takeuchi T, Imaizumi T. High plasma level of remnant-like particle cholesterol in the metabolic syndrome. Diabetes Care. 2005;28:2514–8.
Kotani K, Sakane N, Taniguchi N. Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome. Med Princ Pract. 2012;21:134–8.
Narushima K, Takada T, Yamanashi Y, Suzuki H. Niemann-pick C1-like 1 mediates alpha-tocopherol transport. Mol Pharmacol. 2008;74:42–9.
Acknowledgments
This work was supported by Bayer Yakuhin, Ltd. (Osaka, Japan). The cost of the publication was supported in part by a Research Grant for Young Investigators of Faculty of Agriculture, Kyushu University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shirouchi, B., Nakamura, Y., Furukawa, Y. et al. Ezetimibe Inhibits Lymphatic Transport of Esterified Cholesterol but Not Free Cholesterol in Thoracic Lymph Duct-Cannulated Rats. Cardiovasc Drugs Ther 26, 427–431 (2012). https://doi.org/10.1007/s10557-012-6403-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-012-6403-3